AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® in Chronic Lymphocytic Leukemia Biotech Investing
IMBRUVICA® Plus VENCLEXTA®/VENCLYXTO® Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia Biotech Investing
Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study Biotech Investing
Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020 Biotech Investing
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial Biotech Investing
New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma Biotech Investing
Amgen and McKesson Launch Strategic Agreement to Advance Cancer Innovation in Communities Biotech Investing
Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets Biotech Investing
AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets Biotech Investing
Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference Biotech Investing
CEO Spotlight: Portage Biotech CEO Dr. Ian Walters Talks Asset Pipeline, Uplist, and Strategic Initiatives in a $20 Billion Sector Biotech Investing
